A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

NCT01038804 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: YM155
DRUG: Docetaxel

Sponsor

Astellas Pharma Inc